Artemis Medicare Services Ltd
P&L
Quarterly Consolidated
vs Q3 FY25
Artemis Medicare Services Ltd Reports 7% Increase in Consolidated Gross Revenue for Q4 FY2024-25
13 May 2025 · 13 May 2025, 12:36 am
Summary
Artemis Medicare Services Ltd has reported a 7% increase in consolidated gross revenue for the quarter ended March 31, 2025, totaling Rs 2,521 Million. The company's gross revenue for the fiscal year (April— March) closed at Rs 2,819 Million, an increase of 6.5% over the same period last fiscal. The Board of Directors have recommended a final dividend of 45% per Equity Share of face value of Re 1 each for FY25.
Key Highlights
- 1
7% increase in consolidated gross revenue for Q4 FY2024-25
- 2
21% growth in EBITDA for Q4 FY2024-25
- 3
60% surge in net profit for Q4 FY2024-25
- 4
6.5% growth in gross revenue for FY2024-25
- 5
Recommended final dividend of 45% per Equity Share for FY25
Management Comments
Onkar Kanwar
Chairman, Artemis Medicare Services Ltd
Artemis concluded FY25 on a strong and positive trajectory, delivering consistent performance and steady growth across the year. We have continued to advance in both clinical excellence and operational capabilities, reaffirming our commitment to provide high-quality, accessible healthcare to the communities we serve. During the year we also inaugurated our third tower, which will be commissioned in a phase-wise manner to accommodate the increasing demand from our growing patient base. To fuel our next growth phase, we raised Rs 330 Crores from the International Finance Corporation (IFC), enabling strategic expansion across Delhi NCR and select Tier 2 cities through both brownfield and greenfield projects. The Board has approved a long-term Operations & Management and Medical Services Agreement for a 300+ bed super-speciality hospital in Raipur. This deal marks a key step in expanding our footprint in Central India and reinforces our mission to deliver advanced healthcare solutions across geographies. As we look ahead, our unwavering focus remains on creating long-term value for our patients, shareholders, and employees, while building Artemis into one of India’s most trusted and respected healthcare brands.
Informational and educational content only. Not investment advice.